Japies schreef:
Hier is het exacte antwoord te vinden tussen vical versus crucell.
Ik heb hier een gevoel bij maar zou graag eerst de reacties van biostefan, soldaat of biocon horen, maar wat biocon al schreef lijkt het te onderschrijven:
[quote=Biocon]
Flosz, het gaat IMO inderdaad over Vical's gedeelte. The boost met de cold-related virus, het adenovirus, wordt dus later getest.
Nabel werkt wel samen met Crucell, dus ik denk dat het virale gedeelte van Crucell kan komen.
[/quote]
Maar wat zou in dit geval de impact zijn voor viral en crucell? Vind het een beetje lastig worden of profiteren ze dan allebei een beetje.
Dr. Gary Nabel: We regard the scientists in the private sector as partners, where we concentrate on major scientific hurdles and proof of concepts in the early stages of development,and they specialize and excel at the many clinical production issues that are vital to the final product. In the end, we hope that these products will be manufactured by the private sector. In our Ebola ADV development, we work with Crucell in Amsterdam. For our plasmid DNA vaccine development, to which we remain equally committed for the generation of a preventative vaccine, we work with Vical, Inc. in San Diego. So we feel that each group plays a vital and complementary role.
-------------
Dr. Gary Nabel: This is the reason to continue to pursue a preventive vaccine, which we described in our previously published work. So we continue to place a high priority on the development of our plasmid DNA vaccine that will serve as the prime for an ADV boost in a preventive vaccine. Briefly, we feel that the preventive vaccine has a role to play, and the newer interventional vaccine also has a role. Whether it becomes necessary to vaccinate everyone is difficult to say and depends on how safe and effective it is.
----------------
Alexandria, Va.: I know of one local company (Genvec) doing work in the adenovirus vaccine world. Are they part of your ebola effort?
Thank you.
Dr. Gary Nabel: We are not working with Genvec on our Ebola effort. We are working with a company named Crucell in the Netherlands. We do work with Genvec on HIV and SARS vaccines using their proprietary adenoviral delivery technology.
--------------------
SOURCE:
discuss.washingtonpost.com/wp-srv/zfo...